{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:22:20Z","timestamp":1787840540914,"version":"build-2784847793"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To investigate the timeline of retinal vascularization and associated risk factors in infants with retinopathy of prematurity (ROP) treated with intravitreal bevacizumab (IVB).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective cohort study was conducted at the ROP clinic of the Khatam Eye Hospital from 2014 to 2023. The study included preterm infants diagnosed with ROP who received IVB injection. The primary outcome measure was the time to complete retinal vascularization, defined as the number of weeks from the IVB injection to the point when vascularization extended to the ora serrata.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The study population comprised 155 (49.7%) female and 157 (50.3%) male neonates. The average gestational age at birth was 28.83 weeks (\u00b12.228), and the average birth weight was 1244.90 g (\u00b1406.291). The mean duration of hospitalization in the neonatal intensive care unit was 33.71 days (\u00b118.193). The mean (standard deviation) age and weight at complete retinal vascularization were 60.92 (15.16) weeks and 6064.01 (1616.87) g, respectively. The mean time interval between IVB injection and complete retinal vascularization was 24.31 (13.64) weeks. Survival analysis revealed that infants born before 30 weeks or weighing &lt;1500 g experienced longer durations to full vascularization (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). In multivariate Cox regression analysis, none of the variables were identified as independent risk factors for the time to complete vascularization.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This study investigated the duration required for complete retinal vascularization in infants with ROP who received IVB injections. In addition, it evaluated the influences of birth weight, age, and gender as critical factors affecting the time to complete vascularization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/joco.joco_189_25","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T09:03:29Z","timestamp":1773824609000},"page":"328-334","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Retinal Vascularization Timeline following Intravitreal Bevacizumab Injection in Infants with Retinopathy of Prematurity: A Retrospective Study"],"prefix":"10.4103","volume":"37","author":[{"given":"Nasser","family":"Shoeibi","sequence":"first","affiliation":[{"name":"Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Mousavi","sequence":"additional","affiliation":[{"name":"Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Abrishami","sequence":"additional","affiliation":[{"name":"Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedeh Maryam","family":"Hosseini","sequence":"additional","affiliation":[{"name":"Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad-Reza","family":"Ansari-Astaneh","sequence":"additional","affiliation":[{"name":"Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojtaba","family":"Abrishami","sequence":"additional","affiliation":[{"name":"Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghodsieh","family":"Zamani","sequence":"additional","affiliation":[{"name":"Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Bakhtiari","sequence":"additional","affiliation":[{"name":"Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahareh","family":"Gharib","sequence":"additional","affiliation":[{"name":"Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Neghabi","sequence":"additional","affiliation":[{"name":"Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad Motamed","family":"Shariati","sequence":"additional","affiliation":[{"name":"Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"R1-20260319","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/dmcn.15468","article-title":"Retinopathy of prematurity","volume":"65","author":"Dammann","year":"2023","journal-title":"Dev Med Child Neurol"},{"key":"R2-20260319","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3345\/cep.2021.00773","article-title":"Retinopathy of prematurity: A review of epidemiology and current treatment strategies","volume":"65","author":"Hong","year":"2022","journal-title":"Clin Exp Pediatr"},{"key":"R3-20260319","doi-asserted-by":"crossref","first-page":"e2021053924","DOI":"10.1542\/peds.2021-053924","article-title":"Retinopathy of prematurity: A global perspective and recent developments","volume":"150","author":"Sabri","year":"2022","journal-title":"Pediatrics"},{"key":"R4-20260319","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.survophthal.2022.11.007","article-title":"Retinopathy of prematurity: A review of pathophysiology and signaling pathways","volume":"68","author":"Fevereiro-Martins","year":"2023","journal-title":"Surv Ophthalmol"},{"key":"R5-20260319","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/jamaophthalmol.2023.0809","article-title":"Epidemiology of retinopathy of prematurity in the US from 2003 to 2019","volume":"141","author":"Bhatnagar","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"R6-20260319","doi-asserted-by":"crossref","first-page":"21977","DOI":"10.1038\/s41598-022-26229-4","article-title":"Risk factors associated with retinopathy of prematurity development and progression","volume":"12","author":"de Las Rivas Ram\u00edrez","year":"2022","journal-title":"Sci Rep"},{"key":"R7-20260319","doi-asserted-by":"crossref","first-page":"101018","DOI":"10.1016\/j.preteyeres.2021.101018","article-title":"Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF)","volume":"88","author":"Tsai","year":"2022","journal-title":"Prog Retin Eye Res"},{"key":"R8-20260319","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3928\/23258160-20170630-06","article-title":"The Epidemiology of retinopathy of prematurity in the United States","volume":"48","author":"Ludwig","year":"2017","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R9-20260319","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ophtha.2014.07.050","article-title":"Pathophysiology and mechanisms of severe retinopathy of prematurity","volume":"122","author":"Hartnett","year":"2015","journal-title":"Ophthalmology"},{"key":"R10-20260319","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1056\/NEJMra1208129","article-title":"Mechanisms and management of retinopathy of prematurity","volume":"367","author":"Hartnett","year":"2012","journal-title":"N Engl J Med"},{"key":"R11-20260319","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1136\/bjo.2006.098582","article-title":"The early treatment for retinopathy of prematurity study: Structural findings at age 2 years","volume":"90","author":"Good","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"R12-20260319","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ophtha.2016.12.025","article-title":"Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: A report by the American Academy of Ophthalmology","volume":"124","author":"VanderVeen","year":"2017","journal-title":"Ophthalmology"},{"key":"R13-20260319","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/IAE.0000000000001125","article-title":"Outcomes after laser versus combined laser and bevacizumab treatment for type 1 retinopathy of prematurity in zone I","volume":"37","author":"Yoon","year":"2017","journal-title":"Retina"},{"key":"R14-20260319","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12886-018-0685-6","article-title":"Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in type-1 and threshold retinopathy of prematurity (ROP)","volume":"18","author":"Li","year":"2018","journal-title":"BMC Ophthalmol"},{"key":"R15-20260319","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","article-title":"Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: A 5-year retrospective analysis","volume":"122","author":"Hwang","year":"2015","journal-title":"Ophthalmology"},{"key":"R16-20260319","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Eng J Med"},{"key":"R17-20260319","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1080\/14767058.2020.1818214","article-title":"Efficacy and safety of intravitreal bevacizumab for the treatment of retinopathy of prematurity: A single-center retrospective review","volume":"35","author":"Frosini","year":"2022","journal-title":"J Matern Fetal Neonatal Med"},{"key":"R18-20260319","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000449530","article-title":"The process of retinal vascularization after Anti-VEGF treatment in retinopathy of prematurity: A comparison study between ranibizumab and bevacizumab","volume":"236","author":"Alyama\u00e7Sukgen","year":"2016","journal-title":"Ophthalmologica"},{"key":"R19-20260319","doi-asserted-by":"crossref","first-page":"e20183061","DOI":"10.1542\/peds.2018-3061","article-title":"Screening examination of premature infants for retinopathy of prematurity","volume":"142","author":"Fierson","year":"2018","journal-title":"Pediatrics"},{"key":"R20-20260319","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40942-022-00364-6","article-title":"Progression of retinal vascularization after intravitreal anti-vascular-endothelial growth factor therapy in retinopathy of prematurity","volume":"8","author":"Mirghorbani","year":"2022","journal-title":"Int J Retina Vitreous"},{"key":"R21-20260319","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s12886-018-0973-1","article-title":"The treatment and risk factors of retinopathy of prematurity in neonatal intensive care units","volume":"18","author":"Leng","year":"2018","journal-title":"BMC Ophthalmol"},{"key":"R22-20260319","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12886-024-03528-0","article-title":"Evaluating the causes of retinopathy of prematurity relapse following intravitreal bevacizumab injection","volume":"24","author":"Milani","year":"2024","journal-title":"BMC Ophthalmol"},{"key":"R23-20260319","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaophthalmol.2022.3988","article-title":"The male to female ratio in treatment-warranted retinopathy of prematurity: A systematic review and meta-analysis","volume":"140","author":"Hoyek","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"R24-20260319","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40942-021-00340-6","article-title":"Growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: A case-control study","volume":"7","author":"Abrishami","year":"2021","journal-title":"Int J Retina Vitreous"}],"container-title":["Journal of Current Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/joco.joco_189_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:24:43Z","timestamp":1787837083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/joco.joco_189_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/joco.joco_189_25","relation":{},"ISSN":["2452-2325"],"issn-type":[{"value":"2452-2325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"2025-07-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}